Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 814 participants.
Also called NCT02229227
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 814 participants
- Registry
-
NCT02229227 -
2014-001821-34
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, Canada, France, Germany, Hungary, Italy, Mexico, Philippines, Poland, South Africa, South Korea, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02229227. Randomized; no masking; primary purpose treatment. Start 2014-11-21 (actual); primary completion 2017-07-24 (actual). Results posted on 2018-06-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Albiglutide
- Intervention (Drug)
- Insulin Glargine and Insulin Lispro
- Lead sponsor
- GlaxoSmithKline
- Collaborator
- PPD Development, LP
Record details
- Record id
cardio:ct-nct02229227- Content hash
ce5f882cf03b7be5451187914ab17528c76c0d8c4a6bab3a3917118ae79c9eea